Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia

Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML). Previously we demonstrated that AML patients with higher miR-29b expression had better response to the hypomethylating agent decitabine. Ther...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Mims, Alice, Walker, Alison R., Huang, Xiaomeng, Sun, Jin, Wang, Hongyan, Santhanam, Ramasamy, Dorrance, Adrienne M., Walker, Chris, Hoellerbauer, Pia, Tarighat, Somayeh S., Chan, Kenneth K., Klisovic, Rebecca B., Perrotti, Danilo, Caligiuri, Michael A., Byrd, John C., Chen, Ching-Shih, Lee, L. James, Jacob, Samson, Mrózek, Krzysztof, Bloomfield, Clara D., Blum, William, Garzon, Ramiro, Schwind, Sebastian, Marcucci, Guido
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3764604/
https://ncbi.nlm.nih.gov/pubmed/23178755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.342
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi